Home > Riviste > Minerva Gastroenterologica e Dietologica > Fascicoli precedenti > Minerva Gastroenterologica e Dietologica 2020 March;66(1) > Minerva Gastroenterologica e Dietologica 2020 March;66(1):29-34

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   Freefree

Minerva Gastroenterologica e Dietologica 2020 March;66(1):29-34

DOI: 10.23736/S1121-421X.19.02649-7

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Role of a berberine-based nutritional supplement in reducing diarrhea in subjects with functional gastrointestinal disorders

Francesco DI PIERRO 1 , Alexander BERTUCCIOLI 2, Rosanna GIUBERTI 3, Mariella SAPONARA 4, Leandro IVALDI 5

1 Velleja Research, Milan, Italy; 2 Department of Biomolecular Sciences (DISB), University of Urbino, Urbino, Italy; 3 S.I.C.T., Milan, Italy; 4 ASL CN1, Cuneo, Italy; 5 Department of Digestive Endoscopy, Ceva Hospital, Ceva, Cuneo, Italy



BACKGROUND: Berberine, an alkaloid obtained by extraction from Berberis spp., is a botanical that is widely used in the nutraceutical sector to control cholesterol and blood glucose levels. It is also a molecule that is effective in limiting diarrhea due to its multi-factorial properties, including its antimicrobial, gut eubiotic and antisecretive actions, and its ability to slow gut motility. In our routine clinical practice, we have suggested the use of a berberine-based nutraceutical, formulated with melatonin and depolymerized guar gum, to patients affected by functional diarrhea (FD) or by diarrhea-type irritable bowel syndrome (IBS-D).
METHODS: We have therefore retrospectively analyzed the clinical effect of such a nutritional supplement in these two sub-groups of patients.
RESULTS: Despite the highly pragmatic scheme of our study, our findings strongly confirm the antidiarrheal properties of berberine and recommend its use in some gut functional diseases characterized by frequent evacuation of mushy and/or watery stools. In fact, even after 30 days of treatment, the berberine-based nutritional supplement significantly reduces diarrheal events by 50-70%. After 90 days, this reduction improves to between 70 and 80%, with a reduction of more than 60% in the number of evacuations per week and with more than 50% of treated subjects demonstrating normalized, according to self-reported Bristol Stool Scale categorization, stool consistency. The product is well tolerated and adherence to the proposed therapy is good. Common side effects of the product are flatulence and meteorism, likely due to the “acarbose-like” berberine effects on gut α-glucosidase.
CONCLUSIONS: Patients, especially those preferring “natural” therapy, can be successfully treated, when affected by a gut functional disease characterized by diarrhea, by berberine-based products.


KEY WORDS: Diarrhea; Melatonin; Berberis

inizio pagina